Symbiosis appoints Angelika Rublack as Senior Business Development Manager

Symbiosis expands global reach with key appointment of Angelika Rublack as Senior Business Development Manager

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in sterile manufacture of injectable drug products, has appointed Angelika Rublack as Senior Business Development Manager to support its expanding global client base and drive growth across several territories.

With 25 years of international sales and key account experience, the last 16 of which have been in the pharmaceutical industry, Angelika brings an extensive knowledge of sterile manufacturing and commercial fill-finish services. 

She joins Symbiosis from global CDMO Siegfried, holding a range of senior commercial roles including Senior Business Development Manager and Head of Sales Office.

Based in Germany, Angelika will play a pivotal role in expanding Symbiosis’ presence across the EU, US and APAC territories, identifying new project opportunities and fostering long-term partnerships within the biopharmaceutical market. Her appointment underscores Symbiosis’ commitment to client-centric growth worldwide.

“I was drawn to Symbiosis because of the company’s clear dedication to meeting customer needs with passion, agility and transparency,” said Angelika. 

“Their culture of collaboration, strategic focus and customer-first mindset aligns perfectly with my experience and values. I’m excited to bring new partnerships to the business and becoming an integral part of Symbiosis’ continued success.”

In her role, Angelika will focus on identifying and securing new project opportunities and nurturing client relationships, leveraging her deep knowledge of complex stakeholder environments and her extensive experience in collaborative, cross-functional client engagement.

“Angelika brings invaluable expertise in sterile manufacturing and commercial fill/finish, and a proven track record of fostering trusted relationships across the biopharma sector,” said Colin MacKay, CEO of Symbiosis. “Her appointment enhances our business development capabilities across Europe as we continue to grow our international client base.”

Angelika joins the company at a time of accelerating demand for flexible, responsive CMO partnerships. Symbiosis’ ability to offer rapid access to GMP sterile manufacturing slots and a reputation for first-class client services, positions the company as a preferred partner for biopharmaceutical companies bringing life-saving therapies to market.
 

You may also like